Scott G. Franzblau
Director, Institute for Tuberculosis Research
Albert Schatz Professor, College of Pharmacy - Pharmaceutical Sciences
Contact
Office Phone:
Email:
Related Sites:
About Heading link
Research Interests:
1) New drug discovery for tuberculosis, non-tuberculous mycobacteria, Lyme Disease and ESKAPE pathogens
2) Antimicrobial assay development
3) Isolation of novel minor bioactive secondary metabolites
Teaching and Supervision Heading link
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PSCI Ph.D. Thesis Research (PSCI 599), 8/23/2021 – 12/3/2021
PHAR 506 (PHAR 506), 2/24/2021 – 2/24/2021
Undergrad Res Exp MedChem&Pcog (PMMP 300), 1/14/2019 – 5/3/2019
Spec Project Med Chem &Pcog (PMMP 390), 1/9/2017 – 4/28/2017
Fund of Drug Action III (PHAR 333), 8/22/2016 – 12/2/2016
Fund of Drug Action III (PHAR 333), 8/22/2016 – 12/2/2016
Lab Tech in Pcog I (PMPG 590), 1/11/2016 – 4/29/2016
Selected Grants
To identify natural product molecules with potential activity against tuberculosis, National Institutes of Health (National Cancer Institute)., 1/6/2023 - 1/5/2025, No Obligated Amount Set; No Anticipated Amount Set
Design, Syntheses and Studies of Novel Antituberculosis Agents, University of Notre Dame., 9/1/2021 - 8/31/2023, Obligated Amount: $185798; Anticipated Amount: $185798
Provide heat inactivated cell suspensions of four mycobacterial strains to EpicGenetics, EpicGenetics., 8/1/2021 - 1/31/2022, Obligated Amount: $3980; Anticipated Amount: $3980
In Vitro testing of candidate anti-tubercular compounds (Master under 109178), Global Alliance for TB Drug Development., 4/1/2021 - 4/30/2023, Obligated Amount: $747690; Anticipated Amount: $747690
★ Modulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb, Global Alliance for TB Drug Development., 4/1/2019 - 3/31/2023, Obligated Amount: $7080805; Anticipated Amount: $7080805
A new paradigm for the creation and mining of microbial libraries for drug discovery, National Institutes of Health (National Institute of General Medical Sciences)., 8/10/2018 - 7/31/2023, Obligated Amount: $2069671; Anticipated Amount: $2069671
Enhancing basic and translational TB research in northern Vietnam, National Institutes of Health., 7/1/2017 - 6/30/2022, Obligated Amount: $52396; No Anticipated Amount Set
A Novel Antibiotic Strategy Exploiting Metabolite Self-Toxicity, Chicago Biomedical Consortium., 3/1/2017 - 2/28/2019, Obligated Amount: $100000; Anticipated Amount: $100000
★ In Vitro Testing of Candidate Anti-Tubercular Compounds (MASTER under 109178), Global Alliance for TB Drug Development., 10/1/2005 - 3/31/2021, Obligated Amount: $10312702; Anticipated Amount: $10312702
Selected Publications
Lee, SY, Shetye, GS, Son, SR, Lee, H, Klein, LL, Yoshihara, JK, Ma, R, Franzblau, SG, Cho, S, Jang, DS. (2023). Anti-Microbial Activity of Aliphatic Alcohols from Chinese Black Cardamom (Amomum tsao-ko) against Mycobacterium tuberculosis H37Rv. Plants, 12, (1). doi:10.3390/plants12010034.
Ristroph, KD, McManus, SA, Shetye, G, Cho, SH, Lee, D, Szekely, Z, Sinko, PJ, Franzblau, SG, Prud’homme, RK. (2022). Targeted Antitubercular Peptide Nanocarriers Prepared by Flash NanoPrecipitation with Hydrophobic Ion Pairing. Advanced Materials Technologies, 7, (11). doi:10.1002/admt.202101748.
Liu, R, Marshall, K, Ma, R, Lien Thi Pham, K, Shetye, G, Liu, Z, Cho, S, Jeong, H, Franzblau, SG, Moraski, GC, Miller, MJ. (2022). Syntheses and studies of deuterated Imdiazo[1,2-a]pyridine-3-carboxamides with potent anti-tuberculosis activity and improved metabolic properties. Bioorganic Chemistry, 128. doi:10.1016/j.bioorg.2022.106074.
Zhou, B, Shetye, G, Wolf, NM, Chen, SN, Qader, M, Ray, GJ, Lankin, DC, Cho, S, Cheng, J, Suh, JW, Franzblau, SG, McAlpine, JB, Pauli, GF. (2022). New Rufomycins from Streptomyces atratus MJM3502 Expand Anti- Mycobacterium tuberculosis Structure-Activity Relationships. Organic Letters, 24, (40), 7265-7270. doi:10.1021/acs.orglett.2c02493.
Ang, CW, Lee, BM, Jackson, CJ, Wang, Y, Franzblau, SG, Francisco, AF, Kelly, JM, Bernhardt, PV, Tan, L, West, NP, Sykes, ML, Hinton, AO, Bolisetti, R, Avery, VM, Cooper, MA, Blaskovich, MAT. (2022). Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection. Journal of Medicinal Chemistry, 65, (19), 13125-13142. doi:10.1021/acs.jmedchem.2c00972.
Luo, W, Huang, Z, Xu, D, Yang, M, Zhu, Y, Shen, L, Chen, S, Tao, X, Bin, W, Hu, Y, Franzblau, SG, Jiang, N, Wei, Y, Wei, X, Ding, CZ. (2022). Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent. Bioorganic and Medicinal Chemistry Letters, 72. doi:10.1016/j.bmcl.2022.128871.
Huang, Z, Luo, W, Xu, D, Guo, F, Yang, M, Zhu, Y, Shen, L, Chen, S, Tang, D, Li, L, Li, Y, Wang, B, Franzblau, SG, Ding, CZ. (2022). Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent. Bioorganic and Medicinal Chemistry Letters, 71. doi:10.1016/j.bmcl.2022.128824.
Brullo, C, Caviglia, D, Spallarossa, A, Alfei, S, Franzblau, SG, Tasso, B, Schito, AM. (2022). Microbiological Screening of 5-Functionalized Pyrazoles for the Future Development of Optimized Pyrazole-Based Delivery Systems. Pharmaceutics, 14, (9). doi:10.3390/pharmaceutics14091770.
Sutherland, HS, Choi, PJ, Lu, GL, Giddens, AC, Tong, AST, Franzblau, SG, Cooper, CB, Palmer, BD, Denny, WA. (2022). Synthesis and Structure–Activity Relationships for the Anti-Mycobacterial Activity of 3-Phenyl-N-(Pyridin-2-ylmethyl)Pyrazolo[1,5-a]Pyrimidin-7-Amines. Pharmaceuticals, 15, (9). doi:10.3390/ph15091125.
Education
Degrees:
B.S, Rutgers University, United States, 1976
MS, University of Arizona, United States, 1978
PhD, University of Arizona, United States, 1982
Postgraduate Training:
Postgraduate, Kurume University, Japan, 1984